HK1106133A1 - Ion binding compositions - Google Patents

Ion binding compositions

Info

Publication number
HK1106133A1
HK1106133A1 HK07111381.7A HK07111381A HK1106133A1 HK 1106133 A1 HK1106133 A1 HK 1106133A1 HK 07111381 A HK07111381 A HK 07111381A HK 1106133 A1 HK1106133 A1 HK 1106133A1
Authority
HK
Hong Kong
Prior art keywords
compositions
hyperkalemia
ion binding
binding compositions
methods
Prior art date
Application number
HK07111381.7A
Other languages
English (en)
Inventor
Dominique Charmot
John Fordtran
Han Ting Chang
Eric Connor
Mingjun Liu
Gerrit Klaerner
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1106133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority claimed from PCT/US2005/010747 external-priority patent/WO2005097072A1/en
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of HK1106133A1 publication Critical patent/HK1106133A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
HK07111381.7A 2004-03-30 2007-10-22 Ion binding compositions HK1106133A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
PCT/US2005/010747 WO2005097072A1 (en) 2004-03-30 2005-03-30 Ion binding compositions

Publications (1)

Publication Number Publication Date
HK1106133A1 true HK1106133A1 (en) 2008-03-07

Family

ID=40774830

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07111381.7A HK1106133A1 (en) 2004-03-30 2007-10-22 Ion binding compositions
HK08100150.8A HK1109338A1 (en) 2004-03-30 2008-01-07 Ion binding polymers and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08100150.8A HK1109338A1 (en) 2004-03-30 2008-01-07 Ion binding polymers and uses thereof

Country Status (14)

Country Link
EP (6) EP2269589B1 (de)
JP (4) JP5600658B2 (de)
KR (5) KR101269766B1 (de)
CN (2) CN102133196B (de)
AT (2) ATE453383T1 (de)
AU (5) AU2010214732B2 (de)
CA (2) CA2806465C (de)
DE (4) DE602005018619D1 (de)
DK (2) DK3219312T3 (de)
ES (6) ES2659386T3 (de)
GB (2) GB2456253B (de)
HK (2) HK1106133A1 (de)
PL (3) PL2269589T3 (de)
PT (3) PT3219312T (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015000268B1 (pt) 2012-07-11 2021-01-26 Koninklijke Philips N.V. interface do paciente, e, conjunto de interface do paciente
CN112291678B (zh) * 2020-04-03 2023-11-21 南京西觉硕信息科技有限公司 一种音频设备
WO2023088111A1 (en) * 2021-11-17 2023-05-25 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN117106852B (zh) * 2023-09-04 2024-03-19 济宁市兖州区检验检测中心 一种快速检测农产品农药残留的检测方法及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3031737A1 (de) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
KR920006865B1 (ko) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
CN1010098B (zh) * 1985-05-25 1990-10-24 赫彻斯特股份公司 α-氟代丙烯酸酯聚合物的制备方法
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
FR2634377B1 (fr) * 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
ATE116859T1 (de) * 1990-07-04 1995-01-15 Marcin Krotkiewski Blutdrucksenkendes präparat.
DE4139747A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Fuellstoffhaltige, optisch aktive perlpolymerisate
DK0684958T3 (da) 1993-02-17 1998-10-19 Btg Int Ltd Polymerer indeholdende guanidinogrupper til anvendelse i terapi
AU6818894A (en) * 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) * 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
WO1996021454A1 (en) 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
TW528597B (en) 1996-03-05 2003-04-21 Mitsubishi Electric Corp Medicament for preventive and/or therapeutic treatment of hyperphosphatemia
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
WO1998003185A1 (fr) * 1996-07-19 1998-01-29 Nikken Chemicals Co., Ltd. Remedes contre l'hyperphosphatemie
DE69737688T2 (de) 1996-10-23 2008-01-31 Dow Global Technologies, Inc., Midland Wasserlösliche polymere für die verminderung der absorption von diätetikem phosphat oder oxalat
AU2446497A (en) 1997-03-25 1998-10-20 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers combined with a calcium supplement for oral administration
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
KR100775154B1 (ko) 1997-12-19 2007-11-12 스미스클라인 비참 코포레이션 바이트-분산성 정제의 제조 방법
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
AU1998200A (en) * 1999-01-07 2000-07-24 Elan Corporation, Plc Multiparticulate oral dosage forms
CA2377739A1 (en) 1999-07-02 2001-01-11 Symyx Technologies, Inc. Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto
DE60029968T2 (de) 1999-08-09 2006-12-21 Sandoz Ag Proteinherstellung
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
PT1239837E (pt) 1999-10-19 2005-05-31 Genzyme Corp Nucleo de comprimido de polimero por compressao directa
WO2002040039A2 (en) 2000-11-20 2002-05-23 Dow Global Technologies Inc. In vivo use of water absorbent polymers
CA2444587C (en) 2001-04-18 2008-10-21 Genzyme Corporation Pharmaceutical compositions of low salt polyallylamine hydrochloride
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
WO2005094384A2 (en) * 2004-03-30 2005-10-13 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances

Also Published As

Publication number Publication date
DK3219312T3 (en) 2019-04-01
EP2184059A2 (de) 2010-05-12
AU2018206706B2 (en) 2020-08-06
AU2012254879B2 (en) 2016-05-19
ES2720612T3 (es) 2019-07-23
EP2269589A3 (de) 2011-10-05
JP5431439B2 (ja) 2014-03-05
GB0906966D0 (en) 2009-06-03
DE112005000708T5 (de) 2007-02-15
AU2010214729A1 (en) 2010-09-23
ES2339571T3 (es) 2010-05-21
DE112005000725T5 (de) 2007-05-03
DE112005000708B4 (de) 2017-12-21
PL2269589T3 (pl) 2014-05-30
EP2158902A1 (de) 2010-03-03
DE602005019992D1 (de) 2010-04-29
ES2388052T3 (es) 2012-10-08
CA2806465A1 (en) 2005-10-20
AU2010214732A1 (en) 2010-09-23
EP3219312B1 (de) 2019-01-30
EP2269590A3 (de) 2011-10-05
PT3219312T (pt) 2019-03-01
AU2010214732B2 (en) 2012-07-12
JP2012031210A (ja) 2012-02-16
AU2018206706A1 (en) 2018-08-02
KR20120130255A (ko) 2012-11-29
PL2184059T3 (pl) 2013-01-31
CN103251571A (zh) 2013-08-21
AU2010214729B2 (en) 2012-08-16
AU2016216697C1 (en) 2019-03-21
CA2829943A1 (en) 2005-10-20
EP2184059A3 (de) 2010-05-19
ATE453383T1 (de) 2010-01-15
JP5600658B2 (ja) 2014-10-01
EP2158902B1 (de) 2017-12-06
EP2269589A2 (de) 2011-01-05
GB2456253B (en) 2009-08-26
JP2012025783A (ja) 2012-02-09
KR20140003661A (ko) 2014-01-09
CA2829943C (en) 2017-03-14
GB2456253A (en) 2009-07-15
HK1109338A1 (en) 2008-06-06
CA2806465C (en) 2016-05-24
KR20110138300A (ko) 2011-12-26
DE112005000725B4 (de) 2017-12-21
AU2012254879A1 (en) 2012-12-13
KR101362509B1 (ko) 2014-02-13
JP2013056909A (ja) 2013-03-28
AU2016216697B2 (en) 2018-04-19
KR101223335B1 (ko) 2013-01-17
EP2269590A2 (de) 2011-01-05
EP2184059B1 (de) 2012-06-27
PL3219312T3 (pl) 2019-07-31
KR20120060920A (ko) 2012-06-12
JP2014040484A (ja) 2014-03-06
GB2456256A (en) 2009-07-15
KR101399238B1 (ko) 2014-05-27
ES2338667T3 (es) 2010-05-11
DE602005018619D1 (de) 2010-02-11
EP3219312A1 (de) 2017-09-20
GB0907161D0 (en) 2009-06-10
AU2016216697A1 (en) 2016-09-08
EP2269589B1 (de) 2013-12-25
JP5671511B2 (ja) 2015-02-18
ES2659386T3 (es) 2018-03-15
CN103251571B (zh) 2016-08-17
KR20130086262A (ko) 2013-07-31
GB2456256B (en) 2009-08-26
CN102133196A (zh) 2011-07-27
PT2269589E (pt) 2014-02-26
CN102133196B (zh) 2015-01-21
ATE460927T1 (de) 2010-04-15
PT2184059E (pt) 2012-07-06
ES2453048T3 (es) 2014-04-03
KR101269766B1 (ko) 2013-05-30
EP3574896A1 (de) 2019-12-04
DK2269589T3 (da) 2014-03-31

Similar Documents

Publication Publication Date Title
GB2430624B (en) Ion binding compositions
WO2005092039A3 (en) Crosslinked amine polymers
GB2446076A (en) Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
EP1831266A4 (de) Vernetzte aminpolymere
GB2446077A (en) Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
WO2007057714A3 (en) Pharmaceutical compositions comprising methotrexate
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2007038801A3 (en) Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
WO2009023544A3 (en) Dosage unit anion-exchange polymer pharmaceutical compositions
WO2008112325A3 (en) Treatment of autoimmune disorders
HK1109338A1 (en) Ion binding polymers and uses thereof
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2004018010A3 (en) Methods of drug delivery using sulphated chitinous polymers
WO2007123686A3 (en) Dpp inhibitors and uses thereof
WO2008070778A3 (en) Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
WO2007116278A3 (en) Antiangiogenic peptide and therapeutic uses thereof
MY146274A (en) Pharmaceutical compositions and methods relating to fucans

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220330